Press releases

29 February, 2016

Regulatory

NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio

On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") decided to carry out a new issue of shares and warrants (units) with preferential right ...

8 May, 2015

Regulatory

NeuroVive completes share issue raising SEK 70 million for the preparation of CicloMulsion®’s clinical trial in the US and commercialization in Europe

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company has completed the directed share issue announced on May 7, 2015, whereby 1,647,059 new share ...

7 May, 2015

Regulatory

NeuroVive announces the intention to raise additional capital through a private placement

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company intends to raise new equity through a private placement directed towards qualified instituti ...

20 February, 2015

Regulatory

NeuroVive completes a directed share issue of SEK 65 million for continued expansion

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed a directed share issue of 1.3 million new shares, whic ...

31 January, 2014

Regulatory

NeuroVive rights issue 270% oversubscribed

NeuroVive Pharmaceutical AB (publ) has completed the rights issue approved by an Extraordinary General Meeting on 13 December 2013. The subscription period was 13-27 January 2014. The rights issue was ...

15 January, 2014

Regulatory

Senior managers’ and Directors’ subscriptions in new issue

Many Directors and senior managers intend to participate in NeuroVive's current rights issue.

18 December, 2013

Regulatory

NeuroVive—SEK 35 m private placement complete, more information on forthcoming SEK 75.8 m rights issue

The private placement reported to the market on 20 November 2013 and approved by the Extraordinary General Meeting (EGM) on 13 December 2013 is now complete.

21 November, 2013

Regulatory

Correction: NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

The news release of 20 November at 5:55 p.m. stated the subscription period for the Rights Issue as 13-27 January 2013. The correct dates should be 13-27 January 2014.

20 November, 2013

Regulatory

NeuroVive proposes resolution on private placement and rights issue totaling approximately SEK 111 m

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ), (the "Company") decided to convene an Extraordinary General Meeting (EGM) and to propose that the Meeting approves a ...